SubsidiaryAug 3, 2026, 05:27 PM
Lantern Pharma Establishes Open-Medicine AI as Separate Company
AI Summary
Lantern Pharma Inc. announced the formal establishment of Open-Medicine AI (OMAI) as a separate company. OMAI will commercialize and expand Lantern's multi-agent AI co-scientist platform, previously known as withZeta.ai, into additional disease areas. This move includes the execution of commercial licensing agreements between Lantern Pharma and OMAI, aligning with the framework outlined in Lantern's recent financing.
Key Highlights
- Lantern Pharma established Open-Medicine AI (OMAI) as a separate company.
- OMAI will commercialize and expand Lantern's multi-agent AI co-scientist platform, previously withZeta.ai.
- Commercial licensing agreements were executed between Lantern Pharma and Open-Medicine AI.
- The global AI drug discovery and development market is projected to exceed $10 billion by 2030.
- OMAI will expand its application across broader disease areas beyond oncology.
- AI Centers of Excellence have been established in Bengaluru, India, and Dallas, Texas.
- The establishment is consistent with agreements from Lantern's May financing.
Price Impact
More from LTRN